Determination of acid β-glucocerebrosidase [ABG] enzyme activity coupled with the determination of LysoGb1 and Lyso-SM will allow for better identification of patients and reduction of false positives for Gaucher Disease and ASMD, eventually leading to the diagnostic confirmation with specific molecular analysis. This evidence concerns the gene A1BG and anterior segment dysgenesis.